BetterLife Pharma (BETRF) Stock Price, News & Analysis

Company Overview

BetterLife Pharma Inc. is a Canadian biotechnology company focused on developing novel treatments for mental health and neurological conditions. Its research programs are centered on pharmaceutical compounds derived from or inspired by psychedelic substances, with the goal of creating therapies that may offer therapeutic benefits without the hallucinogenic effects associated with some traditional psychedelics.

The company’s development programs have included BETR-001, a synthetic derivative of lysergic acid diethylamide (LSD) being studied for potential applications in depression and other neuropsychiatric disorders, and BETR-002, an ibogaine-derived compound being investigated for substance-use disorders and related conditions. BetterLife has also pursued research involving pain and other central nervous system indications. These programs remain subject to preclinical and clinical development, regulatory review and approval.

BetterLife Pharma is headquartered in Canada and has conducted research and development activities through relationships with scientific, clinical and regulatory organizations. The company has been led by Fahar Merchant, who has served as its president and chief executive officer. Information about its product candidates and corporate activities may change as development programs advance.

Key Stats

• Today's Range: $0.20 to $0.24
• 50-Day Range: $0.15 to $0.30
• 52-Week Range: $0.03 to $0.33
• Volume: 71,327 shs
• Average Volume: 111,368 shs
• Market Capitalization: $40.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BetterLife Pharma Stock Analysis - MarketRank™

BetterLife Pharma scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BetterLife Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BetterLife Pharma is -24.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BetterLife Pharma is -24.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of BetterLife Pharma has been sold short.

Short Interest Ratio / Days to Cover

BetterLife Pharma has a short interest ratio ("days to cover") of 0.67, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BetterLife Pharma has recently decreased by 57.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BetterLife Pharma does not currently pay a dividend.

Dividend Growth

BetterLife Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.11

News Sentiment

BetterLife Pharma has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for BetterLife Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BetterLife Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.77% of the stock of BetterLife Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.01% of the stock of BetterLife Pharma is held by institutions.

Company Calendar

• Last Earnings: 9/29/2026
• Today: 10/01/2026
• Fiscal Year End: 1/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:BETRF
• CIK: 1464165
• Web: www.abetterlifepharma.com
• Phone: 604-221-0595
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,383.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.04
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: -8.03

Miscellaneous

• Outstanding Shares: 170,115,000
• Free Float: 110,966,000
• Market Cap: $40.98 million
• Optionable: Not Optionable
• Beta: 0.22